v3.25.3
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net loss $ (19,976) $ (17,436)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 309 311
Stock-based compensation 1,017 1,208
Non-cash lease expense 153 216
Fixed assets write-off 34
Changes in operating assets and liabilities:    
R&D tax credit incentive receivable (411)
Prepaid expenses and other assets 1,062 575
Accounts payable 174 274
Accrued compensation expenses 14 (25)
Accrued expenses 57 (131)
Net cash used in operating activities (17,601) (14,974)
Cash flows from investing activities:    
Purchases of property and equipment (899) (260)
Net cash used in investing activities (899) (260)
Cash flows from financing activities:    
Issuance of common stock and warrants in connection with the Securities Purchase Agreement, net of issuance costs 13,687
Issuance of common stock in connection with the 2025 Private Sales Transaction, net of issuance costs 2,593
Gross proceeds from insurance premium loan 355 379
Payments on insurance premium loan (237)
Net proceeds from issuance of common stock in connection with the Sales Agreement, net of issuance costs (28) 160
Net cash provided by financing activities 2,683 14,226
Effect of exchange rate changes on cash and cash equivalents 93
Net decrease increase in cash, cash equivalents and restricted cash (15,724) (1,008)
Cash, cash equivalents and restricted cash balance at beginning of period 19,690 21,992
Cash, cash equivalents and restricted cash balance at end of period 3,966 20,984
Cash paid during the period for:    
Income taxes 2 2
Non-cash investing and financing activities:    
Purchases of property and equipment in accounts payable and accrued expenses $ 443

Source

PDF HTML
ZIP XBRL